[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344985-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344985-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pan-cancer-analysis-of-wrn-from-multi-omics-biomarker-discovery-to-therapy-guiding-functional-evidence","Pan-Cancer Analysis of WRN - From Multi-Omics Biomarker Discovery to Therapy-Guiding Functional Evidence","","Pan-cancer analysis investigates the RecQ helicase WRN as a biomarker and therapy-guiding target across diverse cancers. Bioinformatics integration from multiple public cancer databases evaluates WRN expression, genomic variation, and interaction pathways, plus associations with immune profiling and drug sensitivity. Functional validation with three cancer cell lines tests the suppressor effects of WRN inactivation, linking WRN dysregulation to prognosis, immune activation, MSI/TMB signatures, and reduced malignant phenotypes. Results support WRN as a potential diagnostic/prognostic marker and therapeutic target.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pan-cancer-analysis-of-wrn-from-multi-omics-biomarker-discovery-to-therapy-guiding-functional-evidence/344985/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-of-wrn-from-multi-omics-biomarker-discovery-to-therapy-guiding-functional-evidence/344985.png","ImageObject",300,407,{"name":42,"@type":43},"Aurora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of this pan-cancer study on WRN?","Question",{"text":63,"@type":64},"To evaluate WRN’s role in cancer development and assess its diagnostic and therapy-guiding potential at the pan-cancer level, including biomarker relevance and functional impact.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were WRN expression and related mechanisms analyzed?",{"text":68,"@type":64},"Multiple public cancer databases were integrated with bioinformatics approaches to assess WRN expression, genetic variation, pathway interactions, immune profiling associations, and links to drug sensitivity and treatment responses.",{"name":70,"@type":61,"acceptedAnswer":71},"What experimental evidence supports WRN as a therapeutic target?",{"text":72,"@type":64},"In vitro validation using WRN inhibitors showed strong suppression of malignant phenotypes—proliferation, clonogenicity, migration, and invasion—in colorectal, endometrial, and ovarian cancer models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344985,1790195305,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","OncoTargets and Therapy  \n Open Access Full Text Article  \nORIGINAL RESEARCH  \nPan-Cancer Analysis of WRN: From Multi-Omics Biomarker Discovery to Therapy-Guiding Functional Evidence  \nQing-Qing Yao 1 , Yue Qi2 , Pei-Qin Shi 3 , Zi-Ye Yang 1 , Pengpeng Qu 1 ,4 , Wen-Wen Zhang4  \n1Department of Gynecological Oncology, Tianjin Central Hospital of Gynaecology Obstetrics, School of Medicine, Nankai University, Tianjin, People’s Republic of China; 2Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, People’s Republic of China; 3Clinical School of Obstetrics and Gynecology Center, Tianjin Medical University, Tianjin, People’s Republic of China; 4Department of Gynecological Oncology, Tianjin Central Hospital of Gynaecology Obstetrics, Tianjin, People’s Republic of China  \nCorrespondence: Wen-Wen Zhang, Department of Gynecological Oncology, Tianjin Central Hospital of Gynaecology Obstetrics, Tianjin, People’s Republic of China, Email [zhangsmell2@hotmail.com](zhangsmell2@hotmail.com); Pengpeng Qu, Department of Gynecological Oncology, Tianjin Central Hospital of Gynaecology Obstetrics, School of Medicine, Nankai University, Tianjin, People’s Republic of China, [Email qu.pengpeng@hotmail.com](Email qu.pengpeng@hotmail.com)  \n\n| Background: The RecQ DNA helicase family member WRN is an important protein for maintaining genome stability. The concept of attention as a synthetic lethal target for MSI-H tumors has garnered significant attention in recent years. However, the role ofWRN in cancer development, diagnosis, and prognosis has not yet been systematically evaluated at the pan-cancer level.\u003Cbr>Methods: On the basis of multiple public cancer databases, we employed bioinformatics techniques to systematically assess WRN expression, variation, and interaction pathways across various cancers, along with the impact ofWRN expression on immune profiling, drug sensitivity, and treatment, as a diagnostic tool. Additionally, we used three cancer cell lines to evaluate the suppressor function of WRN inactivation.\u003Cbr>Results: WRN is highly expressed in rapidly proliferating tissues and is dysregulated in a cancer-specific manner, particularly in tumors with hereditary DNA repair deficiencies and myeloid malignancies. WRN expression and variants are correlated with prognosis and immune activation potential in cancers. In digestive cancer and endometrial cancer with a high proportion of MSI-H tumors, WRN is positively associated with MSI/TMB signatures. Pharmacogenomic analyses revealed significant correlations between WRN expression levels and sensitivity to the DNA synthesis inhibitors PI3K, ALK, and IFG1R and other target agents and immunomodulators. In vitro validation using WRN inhibitors demonstrated potent suppression of malignant phenotypes (proliferation, clonogenicity, migration, invasion) in colorectal, endometrial, and ovarian cancer models.\u003Cbr>Conclusion: Our study suggests that WRN plays a role in cancer diagnosis and therapy, especially in cancers characterized by replicative stress or defective DNA damage repair, and that WRN can serve as a potential target for cancer immunotherapy or targeted therapies and as a prognostic marker for certain tumors.\u003Cbr>Keywords: WRN, diagnostic marker, tumor target therapy, genomic instability, pan-cancer analysis |\n| --- |\n| Introduction\u003Cbr>The ability of cells to maintain and regulate genomic stability is crucial for internal balance, and deficiencies in maintaining genomic stability form the basis of many developmental disorders and human diseases, including cancer and premature aging.1,2 Unexpected mutations arising during DNA replication, cell division, and cellular repair can cause genomic instability, thereby increasing the rate of spontaneous mutations and lead to the accumulation of genetic alterations that drive tumor development.3 The genetic composition of cancerous cells varies in terms of the number and type of alterations, resulting in tumor heteroge","cbCaihaUcchoDKjE","https://ap.wps.com/l/cbCaihaUcchoDKjE","pdf",20223730,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What is the main purpose of this pan-cancer study on WRN?\",\"answer\":\"To evaluate WRN’s role in cancer development and assess its diagnostic and therapy-guiding potential at the pan-cancer level, including biomarker relevance and functional impact.\"},{\"question\":\"How were WRN expression and related mechanisms analyzed?\",\"answer\":\"Multiple public cancer databases were integrated with bioinformatics approaches to assess WRN expression, genetic variation, pathway interactions, immune profiling associations, and links to drug sensitivity and treatment responses.\"},{\"question\":\"What experimental evidence supports WRN as a therapeutic target?\",\"answer\":\"In vitro validation using WRN inhibitors showed strong suppression of malignant phenotypes—proliferation, clonogenicity, migration, and invasion—in colorectal, endometrial, and ovarian cancer models.\"}]","Pan-Cancer Analysis of WRN - From Multi-Omics Biomarker Discovery to Therapy-Guiding Functional Evidence | PDF",1790056097,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48d505efae74aa3df2223062139669ab.webp",983,1272,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69e652bba3b12928cf52fbca086d8358.webp",982,1270,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a9ee8f8f41e41ffbdb10c2be15d0cb5.webp",981,1269,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6af33577967166acb2c7bc60a709a7b7.webp",980,1268]